Skip to main content
    P

    Palisade Bio Inc (PALI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.03
    -0.09 (-8.04%)

    Market Cap: $201.01M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Palisade Bio Inc (PALI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Palisade Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$16.78M, operating cash flow was -$10.85M and free cash flow was -$10.85M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$14.62M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $18.06M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$250.00KN/A100.0%-5228.0%-4920.0%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$15.39K-94.1%100.0%-56071.8%-54252.6%
    Dec 2018$260.00K0.0%100.0%-3176.7%-1894.1%
    Dec 2017$260.00K+1500.4%100.0%-5118.1%-6025.4%
    Dec 2016$16.25KN/A100.0%-127027.2%-129721.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$250.00K$0$0$0$15.39K$260.00K$260.00K$16.25K
    Gross profit$0$0$250.00K$0$0$0$15.39K$260.00K$260.00K$16.25K
    Research and development$10.19M$9.06M$6.89M$6.55M$32.55M$3.10M$4.06M$3.96M$8.10M$13.16M
    Operating income-$18.06M-$14.86M-$13.07M-$15.72M-$41.85M-$9.30M-$8.63M-$8.26M-$13.31M-$20.64M
    Net income-$16.78M-$14.44M-$12.30M-$14.26M-$26.62M-$10.32M-$8.35M-$4.92M-$15.67M-$21.07M
    EBITDA-$16.77M-$14.42M-$12.28M-$14.24M-$24.50MN/A-$8.27M-$4.80MN/A-$19.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$500.00K$0$0$0$0$0$4.00K$0$0$0-$250.00K
    Gross profit$0$500.00K$0N/A$0$0$0$2.00K$0$0$0-$304.00K
    Operating income-$15.70M-$11.70M-$10.75M-$9.98M-$2.92M-$2.84M-$2.31M-$3.38M-$3.59M-$4.21M-$3.67M-$3.15M
    Net income-$14.62M-$10.57M-$9.60M-$8.90M-$2.87M-$2.78M-$2.23M-$3.34M-$3.49M-$4.08M-$3.53M-$2.97M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $71.00K by $133.31M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$134.34M$10.88M$14.05M$15.76M$12.51M$3.02M$6.58M$7.68M$13.88M$22.60M
    Current assets$134.22M$10.49M$13.33M$14.73M$11.51M$896.00K$5.65M$6.51M$12.45M$20.90M
    Cash and equivalents$133.38M$9.82M$12.43M$12.38M$10.49M$713.00K$5.11M$5.79M$6.67M$15.19M
    Total liabilities$4.96M$3.39M$2.74M$3.28M$5.15M$10.12M$1.46M$1.63M$5.37M$11.27M
    Short-term debt$71.00K$79.00K$158.00K$88.00K$199.00K$578.00K$140.00KN/AN/A$3.71M
    Long-term debtN/AN/AN/AN/AN/A$94.00KN/AN/A$1.88K$18.21K
    Shareholder equity$129.38M$7.49M$11.31M$12.48M$7.37M-$16.60M$5.13M$6.05M$8.52M$11.33M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$118.55M$127.31M$133.31M$134.34M$6.97M$6.67M$8.19M$10.88M$9.34M$12.87M$12.65M$14.05M
    Total liabilities$6.11M$5.57M$5.95M$4.96M$3.76M$4.05M$2.86M$3.39M$2.73M$2.92M$2.59M$2.74M
    Cash and equivalents$113.61M$125.17M$132.63M$133.38M$5.23M$5.42M$7.23M$9.82M$8.04M$11.35M$11.28M$12.43M
    Shareholder equity$112.44M$121.75M$127.36M$129.38M$3.21M$2.62M$5.33M$7.49M$6.61M$9.95M$10.06M$11.31M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$10.85M-$12.19M-$11.13M-$13.36M-$14.77M-$4.77M-$7.26M-$7.69M-$13.42M-$15.62M
    Capital expenditures$0$0$4.00K$10.00K$0$6.00K$6.00K$1.71K$11.40K$98.09K
    Free cash flow-$10.85M-$12.19M-$11.14M-$13.37M-$14.77M-$4.77M-$7.26M-$7.69M-$13.43M-$15.71M
    Dividends paidN/AN/AN/AN/A$99.00KN/AN/AN/AN/AN/A
    Share repurchases$618.00K$576.00K$617.00K$627.00K$67.00K$0N/AN/AN/AN/A
    Investing cash flow$0$0-$4.00K-$10.00K-$54.00K-$6.00K$0$5.00M-$94.05K$2.36M
    Financing cash flow$134.44M$9.58M$11.19M$15.26M$24.61M$1.89M$6.59M$1.81M$4.99M$23.74M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$11.76M-$7.60M-$3.89M-$3.14M-$3.55M-$1.82M-$2.33M-$2.38M-$3.13M-$3.50M-$3.18M-$2.75M
    Free cash flowN/AN/A-$3.89M-$3.14M-$3.55M-$1.82M-$2.33M-$2.38M-$3.13M-$3.50M-$3.18M-$2.75M
    Last 12 quarters

    Frequently Asked Questions About PALI

    What is Palisade Bio's annual revenue?

    Palisade Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Palisade Bio profitable?

    No. Palisade Bio reported net income of -$16.78M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PALI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.85M minus capital expenditures of $0 produced free cash flow of -$10.85M.

    How much debt does Palisade Bio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $71.00K and cash and equivalents of $133.38M.